À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ© INOVELON? Âú×ãÈ«°¸ÀýÑо¿ÒªÇó

11ÔÂ2ÈÕ  £¬ÈÕ±¾ºñÉúÀͶ¯Ê¡£¨MHLW£©½â³ýÁËÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ©INOVELON?Ƭ¼Á100mgºÍ200mg£¨Í¨ÓÃÃû£ºrufinamide£©×÷ΪÆäËû¿¹ñ²ðïÒ©ÎAED£©µÄ¸¨ÖúÁÆ·¨ÓÃÓÚÖÎÁÆÂ×ŵ¿Ë˹-¼Ó˹ÍÐ×ÛºÏÕ÷£¨LSG£©Åú¼þÖÐËùÐèµÄÉÏÊкóÊÓ²ìÐÔÑо¿  £¬¼´È«°¸ÀýÑо¿µÄÒªÇó¡£

2013Äê3Ô  £¬ÈÕ±¾ºñÉúÀͶ¯Ê¡Åú×¼À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ©INOVELON?×÷ΪÆäËû¿¹ñ²ðïÒ©ÎïµÄ¸¨ÖúÁÆ·¨  £¬ÓÃÓÚÖÎÁÆÅãͬLSGµÄÇ¿Ö±ÐԺͷÇÇ¿Ö±ÐÔñ²ðï·¢×÷ʱ·¢ÏÖ¸ÃÒ©Îï¶ÔÆäËû¿¹ñ²ðïÒ©ÎïµÄ·´Ó³²»×㡪¡ª¡°ÓÉÓÚÈÕ±¾ÁÙ´²ÊÔÑéÖÐÄÉÈëµÄÊÜÊÔÕßÊýÁ¿·Ç³£ÓÐÏÞ  £¬ÒªÇó¶Ô·þÓøÃÒ©Æ·µÄËùÓл¼Õß½øÐÐÉÏÊкóÊÓ²ìÐÔÑо¿  £¬Ö±ÖÁÀÛ¼ÆÒ»¶¨ÊýÁ¿µÄ»¼ÕßÊý¾Ý  £¬ÒÔ±ãʶ±ðʹÓøòúÎïÖÎÁÆ»¼ÕßµÄÅä¾°ÐÅÏ¢  £¬ÊÕ¼¯¸Ã²úÎïÉÏÊкóÔçÆÚµÄÄþ¾²ÐÔºÍÓÐЧÐÔÊý¾Ý  £¬´Ó¶ø½ÓÄÉÐëÒªµÄ´ëÊ©À´È·±£Ò©Æ·µÄÕýȷʹÓá£

×÷Ϊ¶ÔËùÓв¡ÀýÑо¿µÄ·ÖÎö½á¹û  £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ìá½»ÁË702Ãû»¼ÕßµÄÄþ¾²ÐÔÊý¾ÝºÍ495Ãû»¼ÕßµÄÁÆЧÊý¾Ý¡£Æ¾¾ÝÌṩµÄÊý¾Ý  £¬ºñÉúÀͶ¯Ê¡ÌåÏÖËùÓв¡ÀýµÄÑо¿½øÐÐÇ¡µ±  £¬ÇÒ½ÓÄÉÁËÐëÒª´ëÊ©È·±£Ò©Æ·µÄÕýȷʹÓà  £¬Âú×ã½â³ýÌõ¼þ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«¼ÌÐøŬÁ¦ÍƹãINOVELON?µÄÕýȷʹÓÃÒªÁì²¢Ìṩ¸ü¶àÓйزúÎïµÄÐÅÏ¢  £¬´Ó¶ø½øÒ»²½±£Ö¤»¼Õß¼°Æä¼ÒÊôµÄÀûÒæ¡£

 

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120